Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease

Benjamin E Peterson; Deepak L Bhatt; Christie M Ballantyne; James A de Lemos; Robert S Rosenson; Mikhail N Kosiborod; Christopher P Cannon; GOULD Investigators

doi:10.1001/jamanetworkopen.2023.4709

Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease

JAMA Netw Open. 2023 Mar 1;6(3):e234709. doi: 10.1001/jamanetworkopen.2023.4709.

Authors

Benjamin E Peterson¹, Deepak L Bhatt², Christie M Ballantyne³, James A de Lemos⁴, Robert S Rosenson⁵, Mikhail N Kosiborod⁶, Christopher P Cannon^{7

8}; GOULD Investigators

Affiliations

¹ St Elizabeth Heart and Vascular Institute, Edgewood, Kentucky.
² Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York.
³ Baylor College of Medicine, Houston, Texas.
⁴ University of Texas Southwestern Medical Center, Dallas.
⁵ Icahn School of Medicine at Mount Sinai, New York, New York.
⁶ Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City.
⁷ Brigham and Women's Hospital Heart and Vascular Center, Boston, Massachusetts.
⁸ Baim Institute for Clinical Research, Boston, Massachusetts.

No abstract available

Plain language summary

This cohort study assesses patterns in treatment of low-density lipoprotein cholesterol using lipid-lowering therapy among patients with and without polyvascular disease.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anticholesteremic Agents*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Lipids

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Lipids